Comparison of anti-EGFR-Fab&amp;rsquo; conjugated immunoliposomes modified with two different conjugation linkers for siRNA delivery in SMMC-7721 cells

Deng, Li; Zhang, Yingying; Ma, Lulu; Xie, Jing; Ke, Xingfa; Lian, Jianhao; Zhao, Qiang; Yan, Bo; Zhang, Jinfeng; Yao, Jianzhong; Chen, Jianming

doi:10.2147/ijn.s47597

Cited by 35 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, TLPD modified with DSPE-PEG-MAL for conjugation with anti-EGFR Fab' was more efficacious in targeting SMMC-7721 hepatocellular carcinoma cells for siRNA delivery as compared to TLPD containing DSPE-PEG-COOH. 2 This study corroborated the fact that distinct conjugation linkers employed for conjugating antibodies with immunoliposomes influences the physicochemical behavior of LPD and antibody conjugation efficacy, thereby influencing their gene silencing attributes. This report will certainly help researchers in selecting linkers for formulating better targeted drug delivery systems, additionally substantiated the higher efficacy of targeted liposomes over nontargeted systems; thereby paving the way toward utilization of smart and advanced drug delivery systems via multifunctional nanosystems.…”

Section: Dear Editorsupporting

confidence: 74%

“…[1][2][3][4] These published studies make considerable advances toward realizing the great potential of RNA interference (RNAi)-based therapeutics. Despite the curability of the cause of diseases by rectifying altered functionalities of proteins, as of yet no technically viable and safe strategy has been established, owing to their various associated challenges.…”

Section: Dear Editormentioning

confidence: 99%

See 1 more Smart Citation

Multifunctional nanosystems: growing sanguinity in siRNA therapy

Badrealam¹,

Owais²

2014

IJN

View full text Add to dashboard Cite

Section: Dear Editorsupporting

confidence: 74%

Section: Dear Editormentioning

confidence: 99%

Multifunctional nanosystems: growing sanguinity in siRNA therapy

Badrealam¹,

Owais²

2014

IJN

View full text Add to dashboard Cite

“…Additionally, the phospholipid portions of the liposomes can be linked with polyethylene glycol (PEG) or polyethyleneimine (PEI) molecules to increase liposome blood stability. PEG and PEI are also functionalized through amine, carboxylic acids or maleimide groups to peptides, antibodies or any other ligands for active targeting [71,157,158]. Several liposomal formulations for cancer therapy have been approved by the Food and Drug Administration (FDA) [159,160], and have shown promising results in preclinical and clinical studies for drug delivery [150,161,162].…”

Section: Assessing Rnai Delivery For Gbm Treatmentmentioning

confidence: 99%

RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials

2017

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common and deadliest type of primary brain tumor with a prognosis of 14 months after diagnosis. Current treatment for GBM patients includes “total” tumor resection, temozolomide-based chemotherapy, radiotherapy or a combination of these options. Although, several targeted therapies, gene therapy, and immunotherapy are currently in the clinic and/or in clinical trials, the overall survival of GBM patients has hardly improved over the last two decades. Therefore, novel multitarget modalities are urgently needed. Recently, RNA interference (RNAi) has emerged as a novel strategy for the treatment of most cancers, including GBM. RNAi-based therapies consist of using small RNA oligonucleotides to regulate protein expression at the post-transcriptional level. Despite the therapeutic potential of RNAi molecules, systemic limitations including short circulatory stability and low release into the tumor tissue have halted their progress to the clinic. The effective delivery of RNAi molecules through the blood-brain barrier (BBB) represents an additional challenge. This review focuses on connecting the translational process of RNAi-based therapies from in vitro evidence to pre-clinical studies. We delineate the effect of RNAi in GBM cell lines, describe their effectiveness in glioma mouse models, and compare the proposed drug carriers for the effective transport of RNAi molecules through the BBB to reach the tumor in the brain. Furthermore, we summarize the most important obstacles to overcome before RNAi-based therapy becomes a reality for GBM treatment.

show abstract

“…Various functional groups are commercially available, enabling a number of different reactions and target moieties to be utilized. 75 Just as polymer-solvent interactions determine the solubility of a polymer in a given solvent, polymer-polymer interactions between the various monomer units of different polymers can induce a certain degree of mixing (or lack thereof) which can be harnessed for biomedical applications. 76 Characterization of PEG and DSPE-PEG-R by gel permeation chromatography is essential before synthesis of a DDS.…”

Section: Conformation Of Pegmentioning

confidence: 99%

Closing the gap: accelerating the translational process in nanomedicine by proposing standardized characterization techniques

Khorasani¹,

Weaver²,

Salvador-Morales³

2014

IJN

View full text Add to dashboard Cite

On the cusp of widespread permeation of nanomedicine, academia, industry, and government have invested substantial financial resources in developing new ways to better treat diseases. Materials have unique physical and chemical properties at the nanoscale compared with their bulk or small-molecule analogs. These unique properties have been greatly advantageous in providing innovative solutions for medical treatments at the bench level. However, nanomedicine research has not yet fully permeated the clinical setting because of several limitations. Among these limitations are the lack of universal standards for characterizing nanomaterials and the limited knowledge that we possess regarding the interactions between nanomaterials and biological entities such as proteins. In this review, we report on recent developments in the characterization of nanomaterials as well as the newest information about the interactions between nanomaterials and proteins in the human body. We propose a standard set of techniques for universal characterization of nanomaterials. We also address relevant regulatory issues involved in the translational process for the development of drug molecules and drug delivery systems. Adherence and refinement of a universal standard in nanomaterial characterization as well as the acquisition of a deeper understanding of nanomaterials and proteins will likely accelerate the use of nanomedicine in common practice to a great extent.

show abstract

Comparison of anti-EGFR-Fab’ conjugated immunoliposomes modified with two different conjugation linkers for siRNA delivery in SMMC-7721 cells

Cited by 35 publications

References 35 publications

Multifunctional nanosystems: growing sanguinity in siRNA therapy

Multifunctional nanosystems: growing sanguinity in siRNA therapy

RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials

Closing the gap: accelerating the translational process in nanomedicine by proposing standardized characterization techniques

Contact Info

Product

Resources

About